Thursday, November 27, pulmonologist Marc Humbert will receive the Grand Prize from the National Institute of Health and Medical Research (Inserm). By honoring a world-renowned pulmonary arterial hypertension (PAH) specialist, Inserm honors pioneers in the exploration of the processes responsible for this rare and serious disease. But it was also his research that led to the innovative treatment, sotatercept, which was authorized in 2024 by the European Medicines Agency.
“What motivates me is finding therapeutic solutions for diseases whose needs are not being met”confided the doctor-researcher, with unfailing politeness, in his office as dean of the medical school at the University of Paris-Saclay. We are at Bicêtre hospital, in Val-de-Marne. It was there that he led the departments of pulmonology and respiratory intensive care, as well as the Inserm unit he founded in 2010 to study PAH.
You have 89.68% of this article left to read. The remainder is provided to customers.
